ArticleJournal of enzyme inhibition and medicinal chemistry2021
Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- 1,2,3-Triazole-Linked Chalcones as Privileged Scaffolds in Anticancer Agents.Archiv der Pharmazie · 2026Article
- Computational study of chalcone-cyanopyrimidine hybrids as LSD1 inhibitors: Assessing the influence of FAD on binding affinity and inhibition.Biochemistry and biophysics reports · 2025Article
- Review
- Histone demethylase inhibitors: developmental insights and current status.Future medicinal chemistry · 2025Review
- Amide linked chalcone derivatives, a promising class of compounds with versatile biological effects.RSC advances · 2025Review
- Excavating medicinal virtues of chalcones to illuminate a new scope in cancer chemotherapy.RSC advances · 2025Review
- LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.Molecules (Basel, Switzerland) · 2023Article
- Anticancer Activity of Chalcones and Its Derivatives: Review and In Silico Studies.Molecules (Basel, Switzerland) · 2023Review
- Discovery of new potent lysine specific histone demythelase-1 inhibitors (LSD-1) using structure based and ligand based molecular modelling and machine learning.RSC advances · 2022Article
- Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone lysine specific demethylase 1 (LSD1) has emerged as an attractive molecule target for the discovery of potently anticancer drugs to treat leukaemia. In this study, a series of novel chalcone derivatives were designed, synthesised and evaluated for their inhibitory activities against LSD1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.